Over the next few days two new contenders for the heavyweight title for weight control drugs face critical regulatory hurdles. After a long and expensive repeat voyage through a late-stage safety study, Orexigen is slated to get the FDA's marketing decision on Contrave by Thursday. And on the same day Novo Nordisk will run through a gamut of questions at an FDA independent panel review of liraglutide 3 mg, with the pharma player betting that it can ultimately get a green light that will open up a new market for its drug that will be worth billions of dollars in added annual sales.
The executive team here at the rapidly expanding headquarters of Novo Nordisk doesn't pull many punches. CEO Lars Rebien S ø rensen is a competitive sort who tends to be blunt, aggressive and forward-thinking; projecting a confident attitude that is reflected by the rest of the execs and right down the line to 40,000 rank-and-file employees around the world.
Combine the blockbuster GLP-1 drug Victoza with a long-acting insulin and you get a treatment greater than the sum of its parts, according to Novo Nordisk, which unveiled promising new data on its diabetes cocktail IDegLira.
The GLP-1 agonist bested Merck's Januvia and Amylin Pharmaceuticals' Byetta once again, this time by helping more patients push their blood sugar levels below a target of 7%.
Sanofi is making a case for why its experimental diabetes drug Lyxumia stands out from existing GLP-1 therapies, as the French drug giant eyes the new med to build up its Lantus-led diabetes franchise amid relentless competition.
GlaxoSmithKline ($GSK) says it has now obtained the final piece in the Phase III puzzle needed to win regulatory approval for the diabetes drug albiglutide, a GLP-1 candidate.
Shares of Amylin Pharmaceuticals ($AMLN) rocketed up more than 40% this morning, fueled by a report that the Bydureon developer had turned down a $22 per share buyout offer from Bristol-Myers Squibb ($BMY).
GlaxoSmithKline ($GSK) has stumbled badly in its first late-stage study of albiglutide, a weekly GLP-1 diabetes drug. Reporting on the top-line results for the first of eight Phase III studies
Eli Lilly ($LLY), Amylin ($AMLN) and Alkermes ($ALKS) have a fresh Bydureon headache on their hands this morning. In a head-to-head study with Victoza, it was Novo Nordisk's new daily GLP-1 diabetes
Yesterday, Novo Nordisk was in the news because its stock was down due to some concerns its long-term prospects didn't really warrant a high share price. Pfizer had put a real damper on enthusiasm